Australian Pharmaceutical Benefits scheme data on utilisation of intravitreal therapy in retinal vein occlusion

Clin Exp Ophthalmol. 2022 Dec;50(9):1097-1100. doi: 10.1111/ceo.14131. Epub 2022 Aug 5.

Authors

Paul Mitchell¹, Prabhjot Juneja², Chao Wang², Rebecca Schnabel³

Affiliations

¹ University of Sydney, Sydney, Australia.
² Prospection Pty Ltd, Sydney, Australia.
³ Allergan, an AbbVie company, Sydney, Australia.

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Australia / epidemiology
Bevacizumab / therapeutic use
Glucocorticoids / therapeutic use
Humans
Intravitreal Injections
Macular Edema* / drug therapy
Pharmaceutical Preparations
Retinal Vein Occlusion* / diagnosis
Retinal Vein Occlusion* / drug therapy
Tomography, Optical Coherence
Treatment Outcome

Substances

Pharmaceutical Preparations
Angiogenesis Inhibitors
Glucocorticoids
Bevacizumab